CoChat

The impact of epidermal growth factor receptor gene status on gefitinib‐treated Japanese patients with non‐small‐cell lung cancer

Ichihara, Shuji, Toyooka, Shinichi, Fujiwara, Yoshiro, Hotta, Katsuyuki, Shigematsu, Hisayuki, Tokumo, Masaki, Soh, Junichi, Asano, Hiroaki, Ichimura, Kouichi, Aoe, Keisuke, Aoe, Motoi, Kiura, Katsuyuki, Shimizu, Kenji, Date, Hiroshi, Shimizu, Nobuyoshi · 2007 · International Journal of Cancer
Cited by 121

The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.

Abstract

We investigated the relationships between genetic factors and clinical outcome in Japanese non‐small‐cell lung cancer (NSCLC) patients treated with gefitinib. Ninety‐eight NSCLC patients who had been treated with gefitinib, were screened for mutations in epidermal growth factor receptor (EGFR) exons 18–21, KRAS exon2, and polymorphisms including the CA simple sequence repeat in intron1 (CA‐SSR1) and single nucleotide polymorphisms in the promoter region (−216G/T and −191C/A), using a PCR‐based assay and direct sequencing. The EGFR copy number status was also evaluated using a fluorescence in situ hybridization assay. EGFR and KRAS mutations were found in 38 (38.8%) and 8 (8.2%) of the 98 patients, respectively. A high EGFR copy number status was identified in 31 (41.3%) of the 75 assessable patients. Drug‐sensitive EGFR mutations limited to exon19 deletions and L858R were independent predictive factors of a stronger sensitivity to gefitinib (p = 0.0002), the overall survival (OS) (p = 0.0036), and prolonged progression‐free survival (PFS) (p < 0.0001). The EGFR copy number status was not related to a sensitivity to gefitinib and prolonged OS and PFS. Regarding polymorphisms, patients with a short CA‐SSR1 showed a prolonged OS as compared with those with a long length in patients with a drug‐sensitive EGFR mutation, although this difference was not significant (p = 0.13). Thus, drug‐sensitive EGFR mutations predict a favorable clinical outcome and a high EGFR copy number may not be related to clinical benefits in gefitinib‐treated Japanese patients with NSCLC. Our findings also suggest that the CA‐SSR1 length may influence the clinical outcome in patients with a drug‐sensitive EGFR mutation. © 2006 Wiley‐Liss, Inc.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/ijc.22513

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 121

Metadata

Authors
Ichihara, S., Toyooka, S., Fujiwara, Y., Hotta, K., Shigematsu, H., Tokumo, M., Soh, J., Asano, H., Ichimura, K., Aoe, K., Aoe, M., Kiura, K., Shimizu, K., Date, H., & Shimizu, N.
Venue
International Journal of Cancer
Publisher
Wiley
Published
2006-12-27
Volume
120
Issue
6
Pages
1239-1247
ISSN
  • 0020-7136 (ISSN-L)
  • 1097-0215
OpenAlex
W2028770753
Cited by
121
References
9
FWCI
9.66
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.